Another tetravalent symmetric antibody, 2MW4691, targets CCR8, a tumor-resident Treg-specific marker, with low CTLA-4 affinity, eliminating intratumoral Tregs via ADCC without compromising CD8+ T cell activation. Here, CD8A is linked to neoplasm.